HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus' heartbeat; and HeraCARE, a digital pregnancy monitor platform for the creation and implementation of digital health solutions for maternity care management. It also develops EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is headquartered in Netanya, Israel.

HeraMED Limited

Hera Med develops and provides innovative medical technology solutions for remote patient monitoring and healthcare management. Self-described as focusing on improving healthcare outcomes.

HMD

COM:HERA-MED

Hera Med

Last Close

0.02

01/11 04:17

Market Cap

15.20M

Beta: -

Volume Today

591.01K

Avg: -

Financials Not Available